In addition, it has been demonstrated for the first time that in the 2-year follow-up the concentration of IL-18 in the serum may reflect the risk of cardiovascular-related death among patients with CKD and AMI in the preceding year. This evidence concerns the gene IL18 and chronic kidney disease.